What is Kane Biotech Financial Strength?
Kane Biotech has the Financial Strength Rank of 2. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.
Warning Sign:
Kane Biotech Inc displays poor financial strength. Usually, this is caused by too much debt for the company.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Kane Biotech did not have earnings to cover the interest expense.
Kane Biotech's debt to revenue ratio for the quarter that ended in Mar. 2024 was 44.22.
As of today, Kane Biotech's Altman Z-Score is -13.33.
Competitive Comparison of Kane Biotech's Financial Strength
For the Biotechnology subindustry, Kane Biotech's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's Financial Strength distribution charts can be found below:
* The bar in red indicates where Kane Biotech's Financial Strength falls into.
Kane Biotech Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Kane Biotech's Interest Expense for the
months ended in Mar. 2024 was C$-0.32 Mil. Its Operating Income for the
months ended in Mar. 2024 was C$-1.19 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$2.07 Mil.
Kane Biotech's Interest Coverage for the quarter that ended in Mar. 2024 is
| Kane Biotech did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Kane Biotech's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Kane Biotech has a Z-score of -13.33, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -13.33 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kane Biotech (TSXV:KNE) Business Description
Traded in Other Exchanges
Address
290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, DermaKB and DermaKB Biofilm are trademarks of the company. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.
Executives
Kane Biotech (TSXV:KNE) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:KNE has been successfully added to your